Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $4.15 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 188,369 shares of the company’s stock after purchasing an additional 4,328 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Teva Pharmaceutical Industries were worth $4,152,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Stifel Financial Corp boosted its stake in shares of Teva Pharmaceutical Industries by 54.0% during the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after buying an additional 23,283 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in shares of Teva Pharmaceutical Industries by 7.2% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock worth $10,983,000 after buying an additional 33,277 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Teva Pharmaceutical Industries by 21.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock worth $4,046,000 after buying an additional 40,218 shares during the last quarter. Sio Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $24,314,000. Finally, Pinnbrook Capital Management LP acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $4,966,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on TEVA. Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Barclays dropped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Bank of America dropped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, March 19th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Stock Down 0.4 %

Teva Pharmaceutical Industries stock opened at $16.18 on Monday. The stock has a market cap of $18.34 billion, a P/E ratio of -11.16, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a twelve month low of $12.51 and a twelve month high of $22.80. The company’s 50-day moving average price is $17.79 and its two-hundred day moving average price is $18.21.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.